To understand the pathophysiologic significance of abnormal serum prostacyclin (PGI2) binding activities in thrombotic thrombocytopenic purpura (TTP), we 
Introduction
Thrombotic thrombocytopenic purpura (TTP)' is a clinical syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, and neurologic and renal abnormalities (1) . The pathophysiologic basis for these clinical manifestations is thought to be due to the deposition of platelet and fibrin thrombi in the microcirculation. Although the pathogenetic mechanisms of this disorder are not entirely clear, recent studies have disclosed several possible mechanisms such as endothelial cell damage by immune complexes and platelet 1. Abbreviations used in this paper: 6KPGF,,,, 6-keto-prostaglandin F.,,,; PPP, platelet-poor plasma; PRP, platelet-rich plasma; PAGE, polyacrylamide gel electrophoresis; PG12, prostacyclin; PGE,, prostaglandin E,; TTP, thrombotic thrombocytopenic purpura. aggregate formation by platelet aggregating factor (2) and the presence of abnormal Factor VIII:von Willebrand Factor multimers (3) . We have recently detected accelerated serum prostacyclin (PG12) degradation (nonenzymatic hydrolysis) in a patient with chronic TTP (4) . Detailed clinical and laboratory correlates suggest that reduced PG12 bioavailability may play an important role in the pathogenesis of TTP. Subsequently, we measured serum PGI2 binding activity by gel filtration and found a significantly lower binding activity in this patient (5) . To understand the pathophysiologic significance of abnormal serum PGI2 binding in TTP, we have investigated the binding defects in three patients with chronic or relapsing TTP.
Methods
Serum. Serial serum samples were obtained from three patients (W.J., a 42-yr-old male; T.G., a 33-yr-old female; and H.S., a 32-yr-old female) who had the typical clinical pentad of fever, microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, and renal dysfunctions. None of the patients had underlying diseases. Patient W.J. (4, 5) and H.S. (6) have been reported. All three patients initially recovered after plasma exchange therapy but relapsed subsequently. Patients W.J. and T.G. relapsed at regular intervals of 3-4 wk and have required plasma therapy for 27 and 30 mo, respectively. Patient H.S. relapsed twice but responded to plasma exchange and/or infusion on each occasion. Serum samples were prepared from the patients and 19 normal subjects by incubating venous blood at 370C for 2 h, centrifuging samples at 1,500 g for 20 min and storing samples at -70'C until use. Fresh and frozen samples gave identical binding and degradation results. SDS polyacrylamide gel electrophoresis (PAGE) was performed on 7.5% polyacrylamide gels according to a modified method of Laemmli (11) . All the reagents were obtained from Bio-Rad Laboratories, including the Tris/acetate/SDS buffer (Tris 24.84 g/liter, acetic acid 11.7 ml/liter, SDS I g/liter, pH of buffer 6.4, pH of gel 6.1). Fraction D, whose protein content was standardized at 33 gg for all samples, was pretreated with SDS and dithiothreitol (Sigma Chemical Co.) and then applied to the SDS-polyacrylamide gels. The protein bands were stained with Coomassie Brilliant Blue.
Results
PGI2 binding characteristics of normal and TTP sera. Two peaks were noted when normal human serum preincubated with PG12 was subjected to gel filtration (Fig. 1) (Fig. 2 B) . Reduction in the binding began to be noted at 0.5 mM PG12 and a hyperbolic dosevresponse curve was obtained. The second approach was to add increasing concentrations of unlabeled PGI2 to the serum and to measure the 6KPGFI. content to peak I (Fig. 2 B) . A similar doseresponse curve was observed. The PGI2 binding of three TTP sera was examined and a reduced first peak was found in each (Fig. 3 A) slower rate than the activity of unbound PG12 (Fig. 4) . In 10 normal sera, there were positive correlations between the PG12 binding, PG12 antiaggregatory activity and 6KPGFIa content in peak I (Table I ). The antiaggegatory activity and 6KPGFIa content of peak I of TTP serum (W.J.) were proportionally reduced when compared with normals.
To confirm that defective binding leads to accelerated PG12 degradation, PG12 was added to normal and TTP sera, and the half-life of PGI2 was determined. The PG12 half- human PRP (3 X 10' platelets/ml) at 37°C for I min before ADP (3 MuM) was added. Peak I exhibited a potent anti-aggregatory activity when it was eluted from the column ('20 min after it was applied to the column). Furthermore, it retained antiaggregatory activity up to 42 min after its addition to the column. Peak II, similar to PGI2 chromatographed in the absence of serum, had no anti-aggregatory activity. significantly shortened in all three TTP sera (Fig. 3 B) . (Table III) . When used alone, Cohn fraction V albumin preparations did not bind PG12, crystalline albumin bound only a small percentage of PGI2, while defatted albumin bound a quantity of PGO2 equivalent to that bound by serum. When these albumin preparations were added in physiologic concentrations (40 mg/ml) to W.J. and H.S. sera, the following results were obtained. Cohn fraction V did not influence the PGI2 binding in H.S. but suppressed the binding in W.J. Crystalline albumin increased the PG12 binding in both patients. Defatted albumin elicited an additive response in PGO2 binding in H.S. serum, but no effect in W.J. serum (Table III) .
Characterization of binding defects in TTP sera. For the reason that TTP sera appear to be deficient in components that normally prevent rapid PG12 hydrolysis and hence increase PGI2 bioavailability, normal serum was studied to identify these protective components. When normal serum was treated (Table IV) . The binding components in fraction D were nondialyzable. The binding activities were completely eliminated by trypsin (I mg/ml), chymotrypsin (1 mg/ml), and by boiling for 3 min.
Neither heating the serum at 560C for 30 min nor exposure to neuraminidase had an effect on binding activity. Further experiments were initiated to isolate the binding proteins. When fraction D was mixed with hydroxylapatite, 85% of the applied protein was unadsorbed and the remaining 15% could be eluted with 1.0 M sodium phosphate buffer at pH 8.5. However, despite a virtually complete recovery of the applied protein, binding activity was undetectable in either fraction (Table V) . Similar loss of binding activity despite good protein recovery was observed with dye ligand chromatography. It is of particular interest to note that despite the fact that 97% of the applied protein was unadsorbed to Orange A and the remaining 3% was completely eluted, there was no significant binding activity in the unadsorbed or the eluted samples. Although a uniform theory could not be afforded to explain these intriguing defects, we speculate that the defects may be due to a deficiency of the binding protein, on the one hand, and its cofactor, on the other. This hypothesis provides a rational explanation for mutual correctability as well as correction of both defects by normal serum and its derivative, fraction D. However, the lack of an appreciable increase in W.J.'s serum PGI2 binding after in vivo plasma infusion tends to mitigate against this hypothesis.
Serum albumin has been proposed as a PG12 stabilizing factor. Dye ligand experiments (Table V) and isoelectrofocusing experiments (albumin, pI 5.0) strongly suggest, however, that an albumin "deficiency" was not responsible for the impaired PGI2 binding observed in these two patients with TTP. This notion is further confirmed by the failure of several commercial human albumin preparations to increase PGI2 binding. Moreover, since the albumin levels in all three TTP sera were normal, the binding defects are unlikely due to albumin abnormalities.
The pathophysiologic significance of abnormal PGI2 binding and stability in TTP remains to be established. One may speculate that this abnormality may play an important role in predisposing patients to recurrent microangiopathy. Following vascular injury, PGI2 production may be stimulated (16, 17) and protein binding may be needed to protect PGI2 from rapid hydrolysis and catabolism (18 
